Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Total Non-Current Liabilities (2016 - 2021)

Historic Total Non-Current Liabilities for Neurocrine Biosciences (NBIX) over the last 12 years, with Q3 2021 value amounting to $663.0 million.

  • Neurocrine Biosciences' Total Non-Current Liabilities fell 446.69% to $663.0 million in Q3 2021 from the same period last year, while for Sep 2021 it was $663.0 million, marking a year-over-year decrease of 446.69%. This contributed to the annual value of $598.8 million for FY2020, which is 815.95% down from last year.
  • Latest data reveals that Neurocrine Biosciences reported Total Non-Current Liabilities of $663.0 million as of Q3 2021, which was down 446.69% from $648.2 million recorded in Q2 2021.
  • In the past 5 years, Neurocrine Biosciences' Total Non-Current Liabilities registered a high of $694.0 million during Q3 2020, and its lowest value of $42.1 million during Q1 2017.
  • For the 5-year period, Neurocrine Biosciences' Total Non-Current Liabilities averaged around $541.4 million, with its median value being $596.3 million (2019).
  • Examining YoY changes over the last 5 years, Neurocrine Biosciences' Total Non-Current Liabilities showed a top increase of 79640.91% in 2017 and a maximum decrease of 875.8% in 2017.
  • Quarter analysis of 5 years shows Neurocrine Biosciences' Total Non-Current Liabilities stood at $445.5 million in 2017, then grew by 7.02% to $476.7 million in 2018, then skyrocketed by 36.77% to $652.0 million in 2019, then decreased by 8.16% to $598.8 million in 2020, then rose by 10.72% to $663.0 million in 2021.
  • Its Total Non-Current Liabilities was $663.0 million in Q3 2021, compared to $648.2 million in Q2 2021 and $619.5 million in Q1 2021.